Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole + BIO-300
|
DCGG4XJ
|
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Abacavir + BIO-300
|
DCC7NC0
|
Abacavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCJ378D
|
ABIRATERONE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCY4M3E
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCY6Z1X
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCDBPMK
|
ABIRATERONE
|
Glioma (Cell Line: SF-539)
|
[3] |
|
ABIRATERONE + BIO-300
|
DC4LKRS
|
ABIRATERONE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCXAJAQ
|
ABIRATERONE
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
ABIRATERONE + BIO-300
|
DCGMH4G
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
ABIRATERONE + BIO-300
|
DCVER8D
|
ABIRATERONE
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
ABIRATERONE + BIO-300
|
DCZ7F0H
|
ABIRATERONE
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
ABIRATERONE + BIO-300
|
DCW9574
|
ABIRATERONE
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
ABIRATERONE + BIO-300
|
DCOJUXG
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCUQOL1
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCEUISK
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
ABIRATERONE + BIO-300
|
DC4ROT5
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCH4V7Z
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCX2JO5
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCDLZLP
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCPKYQB
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCBGA2Q
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCBPDWP
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCJDGFG
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCHJHEU
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCT80CC
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCCMCPF
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCSDS32
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
ABIRATERONE + BIO-300
|
DC72CT0
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCHOEY1
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCWA9WR
|
ABIRATERONE
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
ABIRATERONE + BIO-300
|
DCFFW46
|
ABIRATERONE
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
Acamprosate + BIO-300
|
DCX9K3B
|
Acamprosate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Acetazolamide + BIO-300
|
DCVZNNM
|
Acetazolamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Aminosalicylic acid + BIO-300
|
DC8RP2C
|
Aminosalicylic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Anastrozole + BIO-300
|
DCW1MKK
|
Anastrozole
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Anastrozole + BIO-300
|
DCWD6PD
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Anastrozole + BIO-300
|
DCHR4L5
|
Anastrozole
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Anastrozole + BIO-300
|
DCBDWPI
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Anastrozole + BIO-300
|
DC9XDVA
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Anastrozole + BIO-300
|
DCXDPNQ
|
Anastrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Anastrozole + BIO-300
|
DCEQNKL
|
Anastrozole
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Anastrozole + BIO-300
|
DC5H0RE
|
Anastrozole
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Anastrozole + BIO-300
|
DCYEZWV
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Anastrozole + BIO-300
|
DC9V2O1
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Anastrozole + BIO-300
|
DCNE4OV
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Anastrozole + BIO-300
|
DC0NMKL
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Anastrozole + BIO-300
|
DC6WDNA
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Anastrozole + BIO-300
|
DC0F0W4
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Anastrozole + BIO-300
|
DCUCYMK
|
Anastrozole
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Anastrozole + BIO-300
|
DCY41ZS
|
Anastrozole
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Anastrozole + BIO-300
|
DCNNTFC
|
Anastrozole
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Anastrozole + BIO-300
|
DC3B8AP
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Anastrozole + BIO-300
|
DCJCC1H
|
Anastrozole
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Anastrozole + BIO-300
|
DC3524J
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Anastrozole + BIO-300
|
DC7402G
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Anastrozole + BIO-300
|
DCHLZYZ
|
Anastrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Anastrozole + BIO-300
|
DC9XCKG
|
Anastrozole
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Anastrozole + BIO-300
|
DC7VC4P
|
Anastrozole
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Anastrozole + BIO-300
|
DCDTAMI
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Anastrozole + BIO-300
|
DCO48KT
|
Anastrozole
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Anastrozole + BIO-300
|
DCZYORF
|
Anastrozole
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Anastrozole + BIO-300
|
DC1A20Y
|
Anastrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Anastrozole + BIO-300
|
DC0HOY3
|
Anastrozole
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Anastrozole + BIO-300
|
DC3WP63
|
Anastrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Anastrozole + BIO-300
|
DCRXEXJ
|
Anastrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Anastrozole + BIO-300
|
DC591OB
|
Anastrozole
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Anastrozole + BIO-300
|
DCSLGFL
|
Anastrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Anastrozole + BIO-300
|
DCDI826
|
Anastrozole
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Anastrozole + BIO-300
|
DCT6OP4
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Armodafinil + BIO-300
|
DCXJJHM
|
Armodafinil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Asenapine + BIO-300
|
DC0R15N
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Auranofin + BIO-300
|
DCXL7HT
|
Auranofin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Azatadine + BIO-300
|
DC76PHF
|
Azatadine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Bepridil + BIO-300
|
DCIFTV0
|
Bepridil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BHV-0223 + BIO-300
|
DC5L0GF
|
BHV-0223
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Aprepitant
|
DCGP7KO
|
Aprepitant
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Meclofenamic acid
|
DCB6QI2
|
Meclofenamic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ribavirin-TP
|
DCV7P61
|
Ribavirin-TP
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Lefaxin
|
DCUH89O
|
Lefaxin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Sertraline
|
DCVW38R
|
Sertraline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Baclofen
|
DCEODI7
|
Baclofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Fulvestrant
|
DCQMWXJ
|
Fulvestrant
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Triiodothyronine
|
DC966JR
|
Triiodothyronine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Aliskiren
|
DC3J7T0
|
Aliskiren
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Dantrolene
|
DC89H1M
|
Dantrolene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Hepzato
|
DC3AR63
|
Hepzato
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Kanamycin
|
DCYEGWQ
|
Kanamycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Triamterene
|
DC9DBOO
|
Triamterene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ixabepilone
|
DCQ87D0
|
Ixabepilone
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Ixabepilone
|
DCSNOJB
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Ixabepilone
|
DC5GNW3
|
Ixabepilone
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Ixabepilone
|
DC18Y85
|
Ixabepilone
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Dactinomycin
|
DC5GVHA
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCPEKXQ
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Dactinomycin
|
DC3A41W
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCWU2Y8
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCWPV81
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCJJIU9
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCS7HIK
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Dactinomycin
|
DC2S7U1
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCZDUDR
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCQU237
|
Dactinomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCZ9VN6
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Dactinomycin
|
DCXW4Q8
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + DFN-15
|
DC73DIS
|
DFN-15
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Lapatinib
|
DCVY6WE
|
Lapatinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Lapatinib
|
DCD226Z
|
Lapatinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Terazosin
|
DC5GS4Q
|
Terazosin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCL658Z
|
PMID28460551-Compound-2
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCZ5TCP
|
PMID28460551-Compound-2
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCGBWQX
|
PMID28460551-Compound-2
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DC3D8JH
|
PMID28460551-Compound-2
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCT8DLT
|
PMID28460551-Compound-2
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Crizotinib
|
DCIFI8A
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Crizotinib
|
DC3SH90
|
Crizotinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Crizotinib
|
DC10B8G
|
Crizotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Crizotinib
|
DCKYF3K
|
Crizotinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Cyclophosphamide
|
DCWVAMX
|
Cyclophosphamide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + LIAROZOLE
|
DCSZI8V
|
LIAROZOLE
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + LIAROZOLE
|
DCY6SA2
|
LIAROZOLE
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Methotrexate
|
DC60GM2
|
Methotrexate
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Methotrexate
|
DCGNDCP
|
Methotrexate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Repaglinide
|
DCH1166
|
Repaglinide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Mephenytoin
|
DCYRHE1
|
Mephenytoin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Anamorelin
|
DCVWGS0
|
Anamorelin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ezetimibe
|
DCMVO8L
|
Ezetimibe
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Plicamycin
|
DC8GI8Q
|
Plicamycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Plicamycin
|
DCIJ2JR
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Plicamycin
|
DC00E21
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Plicamycin
|
DCN032M
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Plicamycin
|
DCITZLE
|
Plicamycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Plicamycin
|
DC2K4L4
|
Plicamycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Plicamycin
|
DCIA5DZ
|
Plicamycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Nilotinib
|
DCW6QSP
|
Nilotinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Thioguanine
|
DCIV4ST
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Thioguanine
|
DCO6XQY
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Thioguanine
|
DCMHAKE
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Thioguanine
|
DCPSDD4
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Thioguanine
|
DCVCO0A
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Thioguanine
|
DC2YL57
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Thioguanine
|
DCJWGPG
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Thioguanine
|
DCGJMR6
|
Thioguanine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Thioguanine
|
DCI0RCL
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Thioguanine
|
DC5K75Y
|
Thioguanine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Thioguanine
|
DC0EGBI
|
Thioguanine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Triapine
|
DC81IF5
|
Triapine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Triapine
|
DCZQF4S
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Triapine
|
DCZ0ID1
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Triapine
|
DCVWHZU
|
Triapine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Everolimus
|
DC3O7AR
|
Everolimus
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Pepstatin
|
DCW1HWK
|
Pepstatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + 10-hydroxycamptothecin
|
DCJTPMR
|
10-hydroxycamptothecin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Rifampin
|
DCCFA7B
|
Rifampin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Topetecan
|
DCYNT8X
|
Topetecan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Topetecan
|
DCPYOCR
|
Topetecan
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
BIO-300 + Topetecan
|
DCJSQAO
|
Topetecan
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Amonafide
|
DC2XRPS
|
Amonafide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Amonafide
|
DCFWU2Y
|
Amonafide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Amonafide
|
DCL4WO5
|
Amonafide
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Amonafide
|
DC36X6W
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Amonafide
|
DC1G5G5
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Amonafide
|
DCU4X53
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Amonafide
|
DCHAS80
|
Amonafide
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Amonafide
|
DCQTJUY
|
Amonafide
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Pralatrexate
|
DC9W0AH
|
Pralatrexate
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Pralatrexate
|
DCWJA87
|
Pralatrexate
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Pralatrexate
|
DC51QZQ
|
Pralatrexate
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Pamidronate
|
DCR5RHE
|
Pamidronate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Isosorbide dinitrate
|
DCX49I2
|
Isosorbide dinitrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Buspirone
|
DCR2ZIK
|
Buspirone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Metyrosine
|
DCY8V8K
|
Metyrosine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Efavirenz
|
DCH6F46
|
Efavirenz
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Terameprocol
|
DCBR77M
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Guanfacine
|
DCPPZRR
|
Guanfacine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + SCH 727965
|
DCVI7H4
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Itraconazole
|
DCKPDTV
|
Itraconazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ifosfamide
|
DCL8NCK
|
Ifosfamide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Ifosfamide
|
DCT031J
|
Ifosfamide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Ifosfamide
|
DCTKX7Z
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Ifosfamide
|
DCDHL5Z
|
Ifosfamide
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Ifosfamide
|
DCJ6PXR
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Ursodeoxycholic acid
|
DC6JD46
|
Ursodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Chlorzoxazone
|
DCH2REF
|
Chlorzoxazone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Dexrazoxane
|
DCRZEHO
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Dexrazoxane
|
DCAL3TM
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Dexrazoxane
|
DC037T8
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Dexrazoxane
|
DCVQQ2W
|
Dexrazoxane
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Dexrazoxane
|
DC7EK3W
|
Dexrazoxane
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Dexrazoxane
|
DCTJ6RI
|
Dexrazoxane
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Metformin
|
DCS3S4R
|
Metformin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Raloxifene
|
DC7K5UQ
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Raloxifene
|
DCH0PXI
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Raloxifene
|
DCLSGXJ
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Phenprocoumon
|
DCE4MOQ
|
Phenprocoumon
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Methoxsalen
|
DCAZCK5
|
Methoxsalen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Galantamine
|
DCZFODJ
|
Galantamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ginsenoside Rb1
|
DCXHEVW
|
Ginsenoside Rb1
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Daidzin
|
DCBFOHF
|
Daidzin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Phensuximide
|
DCK096I
|
Phensuximide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCMYOIZ
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC8J3L7
|
Bendamustine hydrochloride
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC03HBQ
|
Bendamustine hydrochloride
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCD71RM
|
Bendamustine hydrochloride
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCT6R7A
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DC7RL2B
|
Bendamustine hydrochloride
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCPD8LK
|
Bendamustine hydrochloride
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCLWPYT
|
Bendamustine hydrochloride
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCDD94C
|
Bendamustine hydrochloride
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZBXNF
|
Bendamustine hydrochloride
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
BIO-300 + Fluspirilene
|
DCKNLNA
|
Fluspirilene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + VR-776
|
DCKJB7P
|
VR-776
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + WAY-100635
|
DCYIBBK
|
WAY-100635
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Armodafinil
|
DCN88A1
|
Armodafinil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Ciprofibrate
|
DCAAN8M
|
Ciprofibrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Mecamylamine
|
DCJW6EN
|
Mecamylamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Sirolimus
|
DCDQTJU
|
Sirolimus
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Sirolimus
|
DCP6HBX
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Sirolimus
|
DCH7KTH
|
Sirolimus
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Sirolimus
|
DCBWTVG
|
Sirolimus
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Mitomycin
|
DC5MFT0
|
Mitomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Mitomycin
|
DCDQZN1
|
Mitomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Mitomycin
|
DC6WZ6L
|
Mitomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Mitomycin
|
DC8BJIW
|
Mitomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Mitomycin
|
DCUVHGO
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Mitomycin
|
DCG4VK0
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Mitomycin
|
DCK6HFM
|
Mitomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Mitomycin
|
DCJC30S
|
Mitomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Mitomycin
|
DCTFWP4
|
Mitomycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Mitomycin
|
DCDXFGY
|
Mitomycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Mitomycin
|
DCZQ0AZ
|
Mitomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Mitomycin
|
DCAVQVN
|
Mitomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Naringenin
|
DCOYE9U
|
Naringenin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCTC2AV
|
Uracil mustard
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Uracil mustard
|
DCO9IG7
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCRT120
|
Uracil mustard
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCK1Z0P
|
Uracil mustard
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCSM05I
|
Uracil mustard
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Uracil mustard
|
DC2WOTU
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCD36IE
|
Uracil mustard
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCM8K3V
|
Uracil mustard
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Uracil mustard
|
DC69TJ3
|
Uracil mustard
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCHX2HL
|
Uracil mustard
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Uracil mustard
|
DCUMYID
|
Uracil mustard
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Uracil mustard
|
DC8CIB0
|
Uracil mustard
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Diphenidol
|
DCL9AEF
|
Diphenidol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Pentamidine
|
DCJQ7HB
|
Pentamidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Vincristine
|
DCFXLB3
|
Vincristine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Vincristine
|
DCREU0P
|
Vincristine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Vincristine
|
DC52PE0
|
Vincristine
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
BIO-300 + Vincristine
|
DC0EHOB
|
Vincristine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Vincristine
|
DCKXUPC
|
Vincristine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Vincristine
|
DCSY7LN
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Vincristine
|
DCXYX9X
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Vincristine
|
DC5M3DL
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Vincristine
|
DC4U7HV
|
Vincristine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Vincristine
|
DCYOJTX
|
Vincristine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Vincristine
|
DC3DUFW
|
Vincristine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Vincristine
|
DC6LBV9
|
Vincristine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + PFK-158
|
DCHLYOQ
|
PFK-158
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Sulfapyridine
|
DCZN7DH
|
Sulfapyridine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Tolvaptan
|
DCE1XH5
|
Tolvaptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Arfolitixorin
|
DCMPTLK
|
Arfolitixorin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Arfolitixorin
|
DCO6IUI
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Arfolitixorin
|
DCALE5O
|
Arfolitixorin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Arfolitixorin
|
DCMHNI8
|
Arfolitixorin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Arfolitixorin
|
DC1NA56
|
Arfolitixorin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Eflornithine
|
DCAWLY9
|
Eflornithine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + PF-02545920
|
DC1PWJM
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Norcisapride
|
DCETY41
|
Norcisapride
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Isoproterenol
|
DC3OVEB
|
Isoproterenol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Etonogestrel
|
DCUUJ5S
|
Etonogestrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Tiagabine
|
DC7VVIT
|
Tiagabine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + GINKGOLIDE A
|
DCM3OTE
|
GINKGOLIDE A
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Fenoprofen
|
DCC220X
|
Fenoprofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Tamoxifen
|
DCP71MR
|
Tamoxifen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Entacapone
|
DCB288A
|
Entacapone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Benserazide
|
DCO4M7Q
|
Benserazide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + JNK-IN-8
|
DCFO55S
|
JNK-IN-8
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Pargyline
|
DCJ3CZZ
|
Pargyline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Idarubicin
|
DCUI1Z5
|
Idarubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Idarubicin
|
DCZ28OB
|
Idarubicin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Methocarbamol
|
DC52VLX
|
Methocarbamol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Imatinib
|
DCJXURL
|
Imatinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Imatinib
|
DCRJYA2
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Imatinib
|
DC61UM6
|
Imatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
BIO-300 + Darunavir
|
DCIY7DF
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Bleomycin
|
DCO50A4
|
Bleomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Bleomycin
|
DCMV8BE
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Bleomycin
|
DCRJHOG
|
Bleomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Bleomycin
|
DC304HQ
|
Bleomycin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
BIO-300 + Bleomycin
|
DC8ZIGX
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Bleomycin
|
DCZ6DFM
|
Bleomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Bleomycin
|
DC2YPZ8
|
Bleomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Bleomycin
|
DCNHC16
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Bleomycin
|
DC6NHMT
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Bleomycin
|
DC354OV
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Bleomycin
|
DCMFEJO
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Bleomycin
|
DCQ8K11
|
Bleomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Bleomycin
|
DCCEQYH
|
Bleomycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Bleomycin
|
DCGKGRE
|
Bleomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Bleomycin
|
DCWDKRP
|
Bleomycin
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Bleomycin
|
DCYSK81
|
Bleomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Bleomycin
|
DCUUJ47
|
Bleomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Bortezomib
|
DCTHK7J
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Tropisetron
|
DCFO7CX
|
Tropisetron
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Mebendazole
|
DC902K9
|
Mebendazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Moricizine
|
DC2O1VV
|
Moricizine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Artemisinin
|
DC0A1KY
|
Artemisinin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Topotecan
|
DCYMMQU
|
Topotecan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Topotecan
|
DCMRLIG
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Topotecan
|
DC1TN9I
|
Topotecan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Topotecan
|
DCMCXOG
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Topotecan
|
DCYZTV0
|
Topotecan
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Topotecan
|
DCB3UOL
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Topotecan
|
DCJE906
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Dopamine
|
DCK8TPZ
|
Dopamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Trimethobenzamide
|
DCS0OW2
|
Trimethobenzamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Enalaprilat
|
DCJLYF2
|
Enalaprilat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Acetohexamide
|
DCOX4QR
|
Acetohexamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Novobiocin
|
DC4D01S
|
Novobiocin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Theophylline
|
DC3J8HM
|
Theophylline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Amiloride
|
DCPI259
|
Amiloride
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Brincidofovir
|
DC9JKYZ
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Valproic Acid
|
DC53K6M
|
Valproic Acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Sorafenib
|
DCJFR48
|
Sorafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Sorafenib
|
DC445KF
|
Sorafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Sorafenib
|
DCBNLMA
|
Sorafenib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Sorafenib
|
DC9HK7Y
|
Sorafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Sorafenib
|
DCAMJU9
|
Sorafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Sorafenib
|
DCBYK4Q
|
Sorafenib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Sorafenib
|
DC1SS10
|
Sorafenib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Sorafenib
|
DCM4RJQ
|
Sorafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Asenapine
|
DCSBG7P
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Romidepsin
|
DCVMLZ9
|
Romidepsin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Romidepsin
|
DC49RSL
|
Romidepsin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Romidepsin
|
DC1CWBL
|
Romidepsin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Azacitidine
|
DCKN854
|
Azacitidine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Azacitidine
|
DCYU5IP
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Azacitidine
|
DC891XI
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Azacitidine
|
DCXYOWX
|
Azacitidine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Pomalidomide
|
DCA3HMM
|
Pomalidomide
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Vinflunine
|
DCINVKA
|
Vinflunine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Vinflunine
|
DCW4QSJ
|
Vinflunine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Vinflunine
|
DC1DGTQ
|
Vinflunine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Vinflunine
|
DCZGARG
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Vinflunine
|
DCM5X09
|
Vinflunine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Vinflunine
|
DCE2RTA
|
Vinflunine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Vinflunine
|
DCS57CK
|
Vinflunine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Mercaptopurine
|
DC0CHQO
|
Mercaptopurine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Mercaptopurine
|
DC9IXGX
|
Mercaptopurine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Mepacrine
|
DC3UUUO
|
Mepacrine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Oxandrolone
|
DCEA95S
|
Oxandrolone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Taxol
|
DCL6C1X
|
Taxol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Taxol
|
DCVHWRA
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Taxol
|
DCN4EVW
|
Taxol
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Pizotyline
|
DCMAXIZ
|
Pizotyline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Zileuton
|
DCBH2J9
|
Zileuton
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Fludarabine
|
DC5O3FP
|
Fludarabine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Fludarabine
|
DCK1DR3
|
Fludarabine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
BIO-300 + Fludarabine
|
DCAGRIF
|
Fludarabine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Fludarabine
|
DC90M3E
|
Fludarabine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Nabilone
|
DC9YLX5
|
Nabilone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Silver sulfadiazine
|
DCERDPV
|
Silver sulfadiazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Testolactone
|
DCVJ7LB
|
Testolactone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Sumatriptan
|
DCMIDE8
|
Sumatriptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Olmesartan medoxomil
|
DC6HG9I
|
Olmesartan medoxomil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Rufinamide
|
DC1WWR0
|
Rufinamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + PMID28870136-Compound-43
|
DCPUK2R
|
PMID28870136-Compound-43
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + PMID28870136-Compound-43
|
DCPXFB6
|
PMID28870136-Compound-43
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + PMID28870136-Compound-43
|
DC09N3D
|
PMID28870136-Compound-43
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCHZZYB
|
Aminolevulinic Acid Hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCQTOKG
|
Aminolevulinic Acid Hydrochloride
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCJ01D6
|
Aminolevulinic Acid Hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCR5528
|
Aminolevulinic Acid Hydrochloride
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DC2TAQD
|
Aminolevulinic Acid Hydrochloride
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Estramustine
|
DC1F7Q2
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Estramustine
|
DCARMUM
|
Estramustine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Digitoxin
|
DCQ6HWG
|
Digitoxin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Digitoxin
|
DCH70R2
|
Digitoxin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Cerivastatin
|
DC22L0F
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Busulfan
|
DCODSHF
|
Busulfan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
BIO-300 + Busulfan
|
DCJS0XJ
|
Busulfan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Busulfan
|
DCCCI8P
|
Busulfan
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Busulfan
|
DC0M0DU
|
Busulfan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Busulfan
|
DC8ZZ0R
|
Busulfan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Atovaquone
|
DCEVCNN
|
Atovaquone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Aciclovir
|
DCE1261
|
Aciclovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Acetohydroxamic Acid
|
DC1GOFQ
|
Acetohydroxamic Acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Dasatinib
|
DCECV2Q
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
BIO-300 + Dasatinib
|
DCUOQHM
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
BIO-300 + Dasatinib
|
DCL6IUP
|
Dasatinib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
BIO-300 + Dasatinib
|
DCXT5TJ
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
BIO-300 + Dasatinib
|
DCEZ9F5
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
BIO-300 + Dasatinib
|
DCDO1LY
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Dasatinib
|
DCALEWI
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
BIO-300 + Dasatinib
|
DCV3L83
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
BIO-300 + Dasatinib
|
DCEQEUY
|
Dasatinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
BIO-300 + Dasatinib
|
DC8455S
|
Dasatinib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
BIO-300 + Dasatinib
|
DCDLAT3
|
Dasatinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
BIO-300 + Dasatinib
|
DCTK65S
|
Dasatinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
BIO-300 + Tacrolimus
|
DC9R6VG
|
Tacrolimus
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Cilostazol
|
DCC7ZC5
|
Cilostazol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + L-165041
|
DCF5WWG
|
L-165041
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
BIO-300 + Mechlorethamine
|
DCGE830
|
Mechlorethamine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Ixabepilone
|
DCDN1VU
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Dactinomycin
|
DCG8ZY9
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Dactinomycin
|
DCIWUPW
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Dactinomycin
|
DCFJKRM
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Dactinomycin
|
DC2OPYZ
|
Dactinomycin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
BIO-300 + Dactinomycin
|
DCKCSQ9
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Dactinomycin
|
DCPICZ9
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Lapatinib
|
DCC1MKW
|
Lapatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Lapatinib
|
DCRTCWK
|
Lapatinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + PMID28460551-Compound-2
|
DCYSBB1
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + PMID28460551-Compound-2
|
DC4PYIO
|
PMID28460551-Compound-2
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + PMID28460551-Compound-2
|
DCGZAU8
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + LIAROZOLE
|
DC9462R
|
LIAROZOLE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Methotrexate
|
DCUNFL1
|
Methotrexate
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Plicamycin
|
DCQXREG
|
Plicamycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Plicamycin
|
DCFDP2A
|
Plicamycin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Plicamycin
|
DCJK9SP
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Plicamycin
|
DCAFHKK
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Plicamycin
|
DCBXG01
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Thioguanine
|
DCS6W7D
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Triapine
|
DCXEIWM
|
Triapine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Triapine
|
DCUIYU8
|
Triapine
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Triapine
|
DCZB2LH
|
Triapine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Triapine
|
DCUI8WP
|
Triapine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Amonafide
|
DCQS7U0
|
Amonafide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Amonafide
|
DC9MV0H
|
Amonafide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Pralatrexate
|
DCEOULW
|
Pralatrexate
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Pralatrexate
|
DC4PTVZ
|
Pralatrexate
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Terameprocol
|
DC55UKF
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Ifosfamide
|
DCG4RIL
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Ifosfamide
|
DC694XT
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Dexrazoxane
|
DCZF9AK
|
Dexrazoxane
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Dexrazoxane
|
DC7VOX4
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Dexrazoxane
|
DCPT4T2
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC6LYSZ
|
Bendamustine hydrochloride
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCKAVL0
|
Bendamustine hydrochloride
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DC695SI
|
Bendamustine hydrochloride
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCWD8MG
|
Bendamustine hydrochloride
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Bendamustine hydrochloride
|
DCTPF96
|
Bendamustine hydrochloride
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Sirolimus
|
DC0LVD6
|
Sirolimus
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Mitomycin
|
DCHGMVY
|
Mitomycin
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Mitomycin
|
DC2H6RF
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Mitomycin
|
DCKF2UC
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Mitomycin
|
DCVUWZR
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Uracil mustard
|
DCMNLLX
|
Uracil mustard
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Uracil mustard
|
DCNY6M6
|
Uracil mustard
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Uracil mustard
|
DCG3C0E
|
Uracil mustard
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Uracil mustard
|
DC88QBP
|
Uracil mustard
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
BIO-300 + Uracil mustard
|
DCQEZGP
|
Uracil mustard
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Vincristine
|
DCHXL81
|
Vincristine
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Vincristine
|
DC2X6UN
|
Vincristine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Vincristine
|
DCPD3VR
|
Vincristine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Arfolitixorin
|
DC1L7KJ
|
Arfolitixorin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Altretamine
|
DC9EGLF
|
Altretamine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Altretamine
|
DC0IG6W
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Imatinib
|
DCXBE5R
|
Imatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Imatinib
|
DCHB5ZM
|
Imatinib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Imatinib
|
DCL4XN1
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Bleomycin
|
DCEC6CR
|
Bleomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Bleomycin
|
DC2VSQR
|
Bleomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Bleomycin
|
DC3D7EE
|
Bleomycin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
BIO-300 + Bleomycin
|
DC01CJE
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Bleomycin
|
DCXWR0K
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Bortezomib
|
DCMOWA4
|
Bortezomib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Bortezomib
|
DCTZOEG
|
Bortezomib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
BIO-300 + Sorafenib
|
DC1AWWZ
|
Sorafenib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Sorafenib
|
DCHFT5A
|
Sorafenib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Romidepsin
|
DCP5DUS
|
Romidepsin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Romidepsin
|
DCFK8FY
|
Romidepsin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
BIO-300 + Romidepsin
|
DCMTA8T
|
Romidepsin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Romidepsin
|
DCFJ0X6
|
Romidepsin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Romidepsin
|
DCJ5PU4
|
Romidepsin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Vinflunine
|
DCB8VR3
|
Vinflunine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
BIO-300 + Mercaptopurine
|
DC4HJO5
|
Mercaptopurine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Mepacrine
|
DC5NOK7
|
Mepacrine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Taxol
|
DCV4AKS
|
Taxol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Fludarabine
|
DCFH5WA
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCPOU65
|
Aminolevulinic Acid Hydrochloride
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCLX5S7
|
Aminolevulinic Acid Hydrochloride
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
BIO-300 + Busulfan
|
DCU4095
|
Busulfan
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
BIO-300 + Dasatinib
|
DC2PFJ1
|
Dasatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
BIO-300 + Dasatinib
|
DCWXCSR
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
BIO-300 + Dasatinib
|
DC6M8RY
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
BIO-300 + Mechlorethamine
|
DCXUHPA
|
Mechlorethamine
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Fulvestrant
|
DCEKSI9
|
Fulvestrant
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Fulvestrant
|
DCCPLYU
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Ruxolitinib
|
DCNZHJN
|
Ruxolitinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCL1PJS
|
Ixabepilone
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCGSYTI
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCE8X2P
|
Ixabepilone
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Ixabepilone
|
DC77HVF
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCRAYZY
|
Ixabepilone
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCRSA7X
|
Ixabepilone
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + Ixabepilone
|
DCKN3I1
|
Ixabepilone
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCA30Q9
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Dactinomycin
|
DC3E4W4
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCHJT6E
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCHNQ7W
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCOJNRP
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCPJF4L
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCISHQ1
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCWXY1W
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCJAVAP
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCYQ0GZ
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCM0U34
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCYA10P
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCXKT7Y
|
Dactinomycin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCCPD8T
|
Dactinomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Dactinomycin
|
DCPL41U
|
Dactinomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + DFN-15
|
DC2TBK7
|
DFN-15
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + DFN-15
|
DCJHVZN
|
DFN-15
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Lapatinib
|
DCNJEOO
|
Lapatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Lapatinib
|
DCCO1N2
|
Lapatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Lapatinib
|
DCK8ZIQ
|
Lapatinib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Lapatinib
|
DC2X8X2
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Lapatinib
|
DCF4HT3
|
Lapatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Lapatinib
|
DCCTYAE
|
Lapatinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Lapatinib
|
DCF7I4X
|
Lapatinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Lapatinib
|
DC2VFDK
|
Lapatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Lapatinib
|
DCJ61CR
|
Lapatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DC5D23N
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCUT44M
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCPOR2U
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCFVENL
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DC092YK
|
PMID28460551-Compound-2
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCKJA31
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCJO46J
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DC3NJDN
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCMYYYV
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCMZIJC
|
PMID28460551-Compound-2
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + PMID28460551-Compound-2
|
DCD6IZY
|
PMID28460551-Compound-2
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Crizotinib
|
DC2OKSY
|
Crizotinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Crizotinib
|
DC6HI5B
|
Crizotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Crizotinib
|
DC0YS05
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Crizotinib
|
DCEH5U0
|
Crizotinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Crizotinib
|
DC3GFBR
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Crizotinib
|
DCS0PHK
|
Crizotinib
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Crizotinib
|
DCWH348
|
Crizotinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Crizotinib
|
DCJ3UJW
|
Crizotinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Crizotinib
|
DCHBFZJ
|
Crizotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + LIAROZOLE
|
DCKRB3O
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + LIAROZOLE
|
DC7Q019
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + LIAROZOLE
|
DCH0KN3
|
LIAROZOLE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Methotrexate
|
DCLN95I
|
Methotrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Methotrexate
|
DC7NHFT
|
Methotrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Methotrexate
|
DCKJFKI
|
Methotrexate
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Plicamycin
|
DCXU6PL
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Plicamycin
|
DCZSMOV
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Plicamycin
|
DC40WK2
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Plicamycin
|
DCRR8LE
|
Plicamycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
BIO-300 + Plicamycin
|
DCHC6KU
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[5] |
|
BIO-300 + Plicamycin
|
DCZ79WG
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
|
BIO-300 + Plicamycin
|
DCCHU7S
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Plicamycin
|
DCCSPKE
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + Plicamycin
|
DC0MTIG
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + Plicamycin
|
DC08JHV
|
Plicamycin
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Plicamycin
|
DCO83MT
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Plicamycin
|
DCC292B
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
BIO-300 + Plicamycin
|
DCD4EFB
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Plicamycin
|
DC0PY6R
|
Plicamycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Plicamycin
|
DCHWEXJ
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Nilotinib
|
DC2NGZC
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Thioguanine
|
DC3681I
|
Thioguanine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Thioguanine
|
DC3AQBQ
|
Thioguanine
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Triapine
|
DCVE6FS
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Triapine
|
DCPVFSW
|
Triapine
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Triapine
|
DC2P7ZH
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Triapine
|
DCFDNOR
|
Triapine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + Triapine
|
DCWJSDT
|
Triapine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + Triapine
|
DCRC62Y
|
Triapine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Topetecan
|
DCSUQJG
|
Topetecan
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
|
BIO-300 + Topetecan
|
DCWUKGQ
|
Topetecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Topetecan
|
DCQP1PZ
|
Topetecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Amonafide
|
DCKVELM
|
Amonafide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Amonafide
|
DC8HW9K
|
Amonafide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
BIO-300 + Amonafide
|
DCQ9NIE
|
Amonafide
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC3SYXH
|
Pralatrexate
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC5JUYU
|
Pralatrexate
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC2KZN3
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Pralatrexate
|
DCMF0HK
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Pralatrexate
|
DCUZSPM
|
Pralatrexate
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC1R7KU
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Pralatrexate
|
DCY20O5
|
Pralatrexate
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Pralatrexate
|
DCIG22O
|
Pralatrexate
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + SCH 727965
|
DCHLWY2
|
SCH 727965
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + SCH 727965
|
DC9HPKT
|
SCH 727965
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Ifosfamide
|
DCK9BM9
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Ifosfamide
|
DCY9GGF
|
Ifosfamide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Dexrazoxane
|
DCG1HEZ
|
Dexrazoxane
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Dexrazoxane
|
DCP6UZN
|
Dexrazoxane
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Docetaxel
|
DCUD45U
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Docetaxel
|
DCKA2C3
|
Docetaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Docetaxel
|
DC0CIWW
|
Docetaxel
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Raloxifene
|
DCHCNQ2
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCUUA2Q
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCPSVKC
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCTI5RQ
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DC6BYV9
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCP9C07
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCRXGG7
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCCIQPG
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DC9PG7A
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCYUDI0
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZGLTG
|
Bendamustine hydrochloride
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCEHGSK
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DC7UDR7
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCR1YRN
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCBZVS8
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCZIBN3
|
Bendamustine hydrochloride
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCKW0CO
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCIADZT
|
Bendamustine hydrochloride
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Bendamustine hydrochloride
|
DCNSDSE
|
Bendamustine hydrochloride
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Sirolimus
|
DCT15VG
|
Sirolimus
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Sirolimus
|
DCF0A6T
|
Sirolimus
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Sirolimus
|
DC1DK3X
|
Sirolimus
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Sirolimus
|
DCCAY37
|
Sirolimus
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Sirolimus
|
DC6UEVU
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Sirolimus
|
DCJ6TTC
|
Sirolimus
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Mitomycin
|
DCQ0G4R
|
Mitomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Mitomycin
|
DC8UW9E
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Mitomycin
|
DC99OM9
|
Mitomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Mitomycin
|
DCUMBOY
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Mitomycin
|
DC8UR2A
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Mitomycin
|
DCBS2XT
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Mitomycin
|
DCSYNTH
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Mitomycin
|
DCXFEUU
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Mitomycin
|
DC60XUB
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
|
BIO-300 + Mitomycin
|
DCJEZ1L
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + Mitomycin
|
DCV2GF9
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Mitomycin
|
DC1PGU8
|
Mitomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Mitomycin
|
DCO4IBL
|
Mitomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + Mitomycin
|
DCW5TCI
|
Mitomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + SY-1425
|
DCJHDKD
|
SY-1425
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCNWRYK
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCHFU0K
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCJD0ZV
|
Uracil mustard
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCGOJZY
|
Uracil mustard
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC2XQ4V
|
Uracil mustard
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC02LQJ
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC5UODE
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCNMFBQ
|
Uracil mustard
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC2V4N8
|
Uracil mustard
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCDRQ84
|
Uracil mustard
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCOL82I
|
Uracil mustard
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC89RYT
|
Uracil mustard
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCFMH6V
|
Uracil mustard
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Uracil mustard
|
DC5FV8H
|
Uracil mustard
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
|
BIO-300 + Uracil mustard
|
DCPYXFO
|
Uracil mustard
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Vincristine
|
DCAEIHX
|
Vincristine
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Vincristine
|
DCT0YWC
|
Vincristine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Vincristine
|
DCKPBVF
|
Vincristine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Vincristine
|
DC6IXPW
|
Vincristine
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Vincristine
|
DCA8125
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Vincristine
|
DCNF0QM
|
Vincristine
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Vincristine
|
DC6DSUS
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Vincristine
|
DCSUW6Q
|
Vincristine
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Vincristine
|
DCVFN7D
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Vincristine
|
DCWMU5H
|
Vincristine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Vincristine
|
DC0DFK4
|
Vincristine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Vincristine
|
DCP5CBG
|
Vincristine
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Vincristine
|
DC3M762
|
Vincristine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Vincristine
|
DCQCZ2Q
|
Vincristine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Vincristine
|
DC7MK4Y
|
Vincristine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + Vincristine
|
DCX2L4H
|
Vincristine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
|
BIO-300 + Vincristine
|
DCGKVQS
|
Vincristine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Altretamine
|
DCZLHXP
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Imatinib
|
DC1XWMT
|
Imatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Imatinib
|
DCCNCMD
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Bleomycin
|
DC2JRFI
|
Bleomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Bleomycin
|
DC85IU0
|
Bleomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Bleomycin
|
DC9OOHQ
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Bleomycin
|
DCSDYQA
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Bleomycin
|
DCSFYUI
|
Bleomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Bleomycin
|
DC13147
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Bleomycin
|
DCTO54C
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Bleomycin
|
DC0OCST
|
Bleomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Bleomycin
|
DCWPQXH
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Bleomycin
|
DC6NCGE
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[5] |
|
BIO-300 + Bleomycin
|
DCRZPG9
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Bleomycin
|
DC2JP98
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Bleomycin
|
DCS8V89
|
Bleomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Bleomycin
|
DCMXPAB
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Bleomycin
|
DCZSDMS
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Bleomycin
|
DC4VNHN
|
Bleomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Bleomycin
|
DCJNYPK
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
BIO-300 + Bleomycin
|
DC01PE4
|
Bleomycin
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
BIO-300 + Bleomycin
|
DCWAAN5
|
Bleomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[5] |
|
BIO-300 + Bleomycin
|
DCFOYZN
|
Bleomycin
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Bleomycin
|
DC43L41
|
Bleomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Bleomycin
|
DCPTKQN
|
Bleomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
|
BIO-300 + Bortezomib
|
DCU17JE
|
Bortezomib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Bortezomib
|
DCXLV26
|
Bortezomib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Bortezomib
|
DCRMZIA
|
Bortezomib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Bortezomib
|
DCEYLUJ
|
Bortezomib
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Bortezomib
|
DCAXV8X
|
Bortezomib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Valrubicin
|
DC302LL
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
BIO-300 + Topotecan
|
DCY7NT1
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Topotecan
|
DCH6ZD9
|
Topotecan
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
BIO-300 + Topotecan
|
DCIT2P9
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
BIO-300 + Chlorambucil
|
DC956IJ
|
Chlorambucil
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Sorafenib
|
DC9X6AJ
|
Sorafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Sorafenib
|
DCR5CSJ
|
Sorafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Sorafenib
|
DCBXWXZ
|
Sorafenib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Sorafenib
|
DCT163G
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Sorafenib
|
DC1CJ3X
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Sorafenib
|
DCVZVBH
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Sorafenib
|
DC0LN5S
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Sorafenib
|
DCHVCB8
|
Sorafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Sorafenib
|
DCOS77K
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Sorafenib
|
DCB98A5
|
Sorafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Sorafenib
|
DC3RG73
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Sorafenib
|
DC2UGGL
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Sorafenib
|
DC8Q8IO
|
Sorafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Sorafenib
|
DCX1PHR
|
Sorafenib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Sorafenib
|
DCZ4X21
|
Sorafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
BIO-300 + Romidepsin
|
DCZ2CU0
|
Romidepsin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Romidepsin
|
DCXULNA
|
Romidepsin
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
BIO-300 + Romidepsin
|
DCHHI9X
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
BIO-300 + Romidepsin
|
DCCKDZN
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Romidepsin
|
DCTAMYK
|
Romidepsin
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Romidepsin
|
DCTILGH
|
Romidepsin
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Romidepsin
|
DCAIDTE
|
Romidepsin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
BIO-300 + Romidepsin
|
DCBCP7G
|
Romidepsin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
|
BIO-300 + Romidepsin
|
DCIQFVP
|
Romidepsin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Romidepsin
|
DCHOUL0
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Romidepsin
|
DCR6JDE
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Romidepsin
|
DCLX41I
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
BIO-300 + Romidepsin
|
DCYRSEC
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + Romidepsin
|
DC3SKS0
|
Romidepsin
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Romidepsin
|
DCWOBRV
|
Romidepsin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
BIO-300 + Romidepsin
|
DCSZ5OY
|
Romidepsin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Romidepsin
|
DC09J6O
|
Romidepsin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
|
BIO-300 + Romidepsin
|
DC5Z8OO
|
Romidepsin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
BIO-300 + Azacitidine
|
DCLRY2X
|
Azacitidine
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Azacitidine
|
DC3ZGZ4
|
Azacitidine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[5] |
|
BIO-300 + Azacitidine
|
DCT4NGN
|
Azacitidine
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
BIO-300 + Azacitidine
|
DC8BIDD
|
Azacitidine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Vinflunine
|
DCAJO7H
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Vinflunine
|
DCFPX4H
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Vinflunine
|
DC4W9SH
|
Vinflunine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Mercaptopurine
|
DC2XE67
|
Mercaptopurine
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
BIO-300 + Mercaptopurine
|
DC66OAN
|
Mercaptopurine
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Mepacrine
|
DCWPD51
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
BIO-300 + Taxol
|
DC8O7QJ
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Taxol
|
DCUNE2M
|
Taxol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
BIO-300 + Taxol
|
DCXZUCT
|
Taxol
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
BIO-300 + Taxol
|
DCN4156
|
Taxol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
BIO-300 + Taxol
|
DC8B9L6
|
Taxol
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Fludarabine
|
DCZSWWZ
|
Fludarabine
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
BIO-300 + Fludarabine
|
DC4OXY5
|
Fludarabine
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Fludarabine
|
DCPPIGR
|
Fludarabine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
BIO-300 + PMID28870136-Compound-43
|
DC30VDR
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
|
BIO-300 + PMID28870136-Compound-43
|
DC5PNL2
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCHZ7S5
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Aminolevulinic Acid Hydrochloride
|
DCARRH9
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Estramustine
|
DCW0C82
|
Estramustine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Estramustine
|
DCVKUMI
|
Estramustine
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
BIO-300 + Digitoxin
|
DCN15US
|
Digitoxin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Busulfan
|
DCPUSEZ
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[5] |
|
BIO-300 + Dasatinib
|
DCC9OE8
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
BIO-300 + Dasatinib
|
DCFAFY8
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
BIO-300 + Dasatinib
|
DCMFWE6
|
Dasatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
BIO-300 + Dasatinib
|
DCE383Q
|
Dasatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
BIO-300 + Dasatinib
|
DCPF31O
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
BIO-300 + Dasatinib
|
DCRWLX7
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
BIO-300 + Dasatinib
|
DCG8YBB
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
BIO-300 + Dasatinib
|
DC9CZZH
|
Dasatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
BIO-300 + Dasatinib
|
DCLQJR5
|
Dasatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
BIO-300 + Dasatinib
|
DCAR7DA
|
Dasatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[5] |
|
BIO-300 + Dasatinib
|
DCQWASF
|
Dasatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
Cabazitaxel + BIO-300
|
DCDNN52
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCQV82G
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC1HKCV
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCHIS3E
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCQLZ5V
|
Cabazitaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Cabazitaxel + BIO-300
|
DCLA0DV
|
Cabazitaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCU2NWH
|
Cabazitaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCMA8A0
|
Cabazitaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCDJYHB
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCDJX8Y
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC9ASEF
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC9OHKE
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC2CJHQ
|
Cabazitaxel
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCDJL2T
|
Cabazitaxel
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCON9OV
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC2QQQV
|
Cabazitaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Cabazitaxel + BIO-300
|
DC5913L
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCPGGX9
|
Cabazitaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCX9UIH
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCE5X1J
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Cabazitaxel + BIO-300
|
DCOOHUB
|
Cabazitaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Cabazitaxel + BIO-300
|
DCQ1U2D
|
Cabazitaxel
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Cevimeline + BIO-300
|
DC8943H
|
Cevimeline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Chlorambucil + BIO-300
|
DCXZQ8V
|
Chlorambucil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Chlorphenesin + BIO-300
|
DCGEWO3
|
Chlorphenesin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Cisatracurium + BIO-300
|
DCG3533
|
Cisatracurium
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Citalopram + BIO-300
|
DC6D15F
|
Citalopram
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Clascoterone + BIO-300
|
DCDUWLF
|
Clascoterone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Clopidogrel + BIO-300
|
DCDTXZR
|
Clopidogrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Crizotinib + BIO-300
|
DC2UY2A
|
Crizotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Crizotinib + BIO-300
|
DC55XAV
|
Crizotinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Crizotinib + BIO-300
|
DCTW16N
|
Crizotinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Crizotinib + BIO-300
|
DCMPORQ
|
Crizotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Crizotinib + BIO-300
|
DC4V59F
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Crizotinib + BIO-300
|
DCEJKQC
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Crizotinib + BIO-300
|
DCFHGAX
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Crizotinib + BIO-300
|
DCG2HKI
|
Crizotinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Crizotinib + BIO-300
|
DCU0MO4
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Crizotinib + BIO-300
|
DC2HJEY
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Crizotinib + BIO-300
|
DCKFGZV
|
Crizotinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Crizotinib + BIO-300
|
DC2FQUV
|
Crizotinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Crizotinib + BIO-300
|
DC20I6M
|
Crizotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Crizotinib + BIO-300
|
DC3LFJ7
|
Crizotinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Crizotinib + BIO-300
|
DCM5ORP
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Crizotinib + BIO-300
|
DCP433B
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Crizotinib + BIO-300
|
DCPNKBQ
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Crizotinib + BIO-300
|
DC0TYGA
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Crizotinib + BIO-300
|
DCDSOD6
|
Crizotinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Crizotinib + BIO-300
|
DCLLCAP
|
Crizotinib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Crizotinib + BIO-300
|
DCLZUQH
|
Crizotinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Crizotinib + BIO-300
|
DC7TMA8
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Crizotinib + BIO-300
|
DCOBCQL
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Crizotinib + BIO-300
|
DCFW6RK
|
Crizotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Crizotinib + BIO-300
|
DCJIKAE
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Crizotinib + BIO-300
|
DCS7K8T
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Crizotinib + BIO-300
|
DC61VKX
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Crizotinib + BIO-300
|
DCWOHO3
|
Crizotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Crizotinib + BIO-300
|
DCW86UA
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Crizotinib + BIO-300
|
DCOL6WJ
|
Crizotinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Crizotinib + BIO-300
|
DCKYTNG
|
Crizotinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Crizotinib + BIO-300
|
DCMDCNI
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Crizotinib + BIO-300
|
DC19Y83
|
Crizotinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Crizotinib + BIO-300
|
DC1U9IE
|
Crizotinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Crizotinib + BIO-300
|
DCPXHPK
|
Crizotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Crizotinib + BIO-300
|
DCXJ0T3
|
Crizotinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Crizotinib + BIO-300
|
DCUAY16
|
Crizotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Crizotinib + BIO-300
|
DCX4C3V
|
Crizotinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Crizotinib + BIO-300
|
DCOT1MY
|
Crizotinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Crizotinib + BIO-300
|
DCGKMDU
|
Crizotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Crizotinib + BIO-300
|
DCFUS34
|
Crizotinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Crizotinib + BIO-300
|
DC8XAKX
|
Crizotinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Crizotinib + BIO-300
|
DCXMRUH
|
Crizotinib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Cycloguanil + BIO-300
|
DCJC4BX
|
Cycloguanil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Dactinomycin + BIO-300
|
DC575WL
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[5] |
|
Dexmedetomidine + BIO-300
|
DC5ZPG4
|
Dexmedetomidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Diazoxide + BIO-300
|
DCWTMYY
|
Diazoxide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Diethylcarbamazine + BIO-300
|
DCS477T
|
Diethylcarbamazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Dihydroergotamine + BIO-300
|
DC04T1E
|
Dihydroergotamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Emetine + BIO-300
|
DCBDQX4
|
Emetine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Endoxifen + BIO-300
|
DC8Z4AJ
|
Endoxifen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Enoxacin + BIO-300
|
DCIW6WG
|
Enoxacin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Epirubicin + BIO-300
|
DCE6DIK
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Epirubicin + BIO-300
|
DCYVVQI
|
Epirubicin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Epirubicin + BIO-300
|
DCHTFOC
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
Epirubicin + BIO-300
|
DCUSWYN
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
Epirubicin + BIO-300
|
DC8XYPO
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
Epirubicin + BIO-300
|
DCTTTH1
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
Eptifibatide + BIO-300
|
DC8JXXN
|
Eptifibatide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Ethambutol + BIO-300
|
DCSQHCL
|
Ethambutol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Ethinyl estradiol + BIO-300
|
DCPAUXA
|
Ethinyl estradiol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
ETHISTERONE + BIO-300
|
DCBHH3K
|
ETHISTERONE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Etomidate + BIO-300
|
DCQU5SP
|
Etomidate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Fosfomycin + BIO-300
|
DCC7SUE
|
Fosfomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Furazolidone + BIO-300
|
DCRI4E5
|
Furazolidone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Gefitinib + BIO-300
|
DCCPUIW
|
Gefitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Gefitinib + BIO-300
|
DC8GV4Z
|
Gefitinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Gefitinib + BIO-300
|
DCALTNT
|
Gefitinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Gefitinib + BIO-300
|
DCWY00V
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Gefitinib + BIO-300
|
DCG5D82
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Gefitinib + BIO-300
|
DCJDY0F
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Gefitinib + BIO-300
|
DCA0CUN
|
Gefitinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Gefitinib + BIO-300
|
DC8W0OK
|
Gefitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Gefitinib + BIO-300
|
DC20F2D
|
Gefitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Gefitinib + BIO-300
|
DCSSCQ8
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Gefitinib + BIO-300
|
DCIZR00
|
Gefitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Gefitinib + BIO-300
|
DCLKGMZ
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Gefitinib + BIO-300
|
DC5A000
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Gefitinib + BIO-300
|
DCL1BE3
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Gefitinib + BIO-300
|
DCQN90O
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Gefitinib + BIO-300
|
DCZ9K1L
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Gefitinib + BIO-300
|
DCLCBOA
|
Gefitinib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Gefitinib + BIO-300
|
DCZQMPC
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Gefitinib + BIO-300
|
DCTGW88
|
Gefitinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Gefitinib + BIO-300
|
DCH93D2
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Gefitinib + BIO-300
|
DC2SMR9
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Gefitinib + BIO-300
|
DCYL39W
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Gefitinib + BIO-300
|
DCYLKKY
|
Gefitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Gefitinib + BIO-300
|
DCH1CQ6
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Gefitinib + BIO-300
|
DCE962A
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Gefitinib + BIO-300
|
DCK5HRR
|
Gefitinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Gefitinib + BIO-300
|
DCMT5ED
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Gefitinib + BIO-300
|
DCWZGAN
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Gefitinib + BIO-300
|
DC7UE7G
|
Gefitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Gefitinib + BIO-300
|
DCMJD40
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Gefitinib + BIO-300
|
DCVRKAH
|
Gefitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Gefitinib + BIO-300
|
DCJQMXN
|
Gefitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Gefitinib + BIO-300
|
DCKLSEW
|
Gefitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Gefitinib + BIO-300
|
DC6LK6K
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Gefitinib + BIO-300
|
DC06CNG
|
Gefitinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Gefitinib + BIO-300
|
DC4693A
|
Gefitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Gefitinib + BIO-300
|
DCAI3GK
|
Gefitinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Gefitinib + BIO-300
|
DCVVQ1V
|
Gefitinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Gefitinib + BIO-300
|
DC8BHAK
|
Gefitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Gefitinib + BIO-300
|
DCVRWVX
|
Gefitinib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Gefitinib + BIO-300
|
DCPGUGI
|
Gefitinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Gefitinib + BIO-300
|
DC7Y74W
|
Gefitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Gefitinib + BIO-300
|
DCI2DVP
|
Gefitinib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Gefitinib + BIO-300
|
DCBLP2G
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Gefitinib + BIO-300
|
DCU4C5Q
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
GS4071 + BIO-300
|
DCDOYOX
|
GS4071
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
GSK2194069 + BIO-300
|
DCP2VTL
|
GSK2194069
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Hydroxychloroquine + BIO-300
|
DC6AJ5M
|
Hydroxychloroquine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Hyodeoxycholic acid + BIO-300
|
DC2ON39
|
Hyodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Imatinib + BIO-300
|
DCC85V2
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Imipramine + BIO-300
|
DCZ7C5U
|
Imipramine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCVXFIO
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCYEWT2
|
Indazole derivative 5
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCKK021
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DC5E3QL
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCPWJ5V
|
Indazole derivative 5
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCNOQ2A
|
Indazole derivative 5
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCX77FK
|
Indazole derivative 5
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Indazole derivative 5 + BIO-300
|
DCQL98S
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
Indazole derivative 5 + BIO-300
|
DCF9LRM
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
Indazole derivative 5 + BIO-300
|
DCO560Z
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
Indazole derivative 5 + BIO-300
|
DC272VJ
|
Indazole derivative 5
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
Indazole derivative 5 + BIO-300
|
DCHNDU0
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
Indazole derivative 5 + BIO-300
|
DCVJNI1
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
JZL195 + BIO-300
|
DCXT28N
|
JZL195
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Lenalidomide + BIO-300
|
DCTFX1X
|
Lenalidomide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Lenalidomide + BIO-300
|
DCP5N8V
|
Lenalidomide
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
Levamisole + BIO-300
|
DCGXXQ8
|
Levamisole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
LIAROZOLE + BIO-300
|
DCDREQ7
|
LIAROZOLE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Lithium Citrate + BIO-300
|
DC5HNGZ
|
Lithium Citrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Loperamide + BIO-300
|
DCIUEKY
|
Loperamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Lumefantrine + BIO-300
|
DCLXXYB
|
Lumefantrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
LY03004 + BIO-300
|
DC6L2EJ
|
LY03004
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Maprotiline + BIO-300
|
DCDUDJ7
|
Maprotiline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Mebutamate + BIO-300
|
DCVFAGO
|
Mebutamate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Memantine + BIO-300
|
DC94JBQ
|
Memantine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Mesalazine + BIO-300
|
DCFTWP4
|
Mesalazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Metaxalone + BIO-300
|
DCM01BZ
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Miconazole + BIO-300
|
DC7BFG2
|
Miconazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Mycophenolic acid + BIO-300
|
DC7LQKS
|
Mycophenolic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Nabilone + BIO-300
|
DCK9TCT
|
Nabilone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Naltrexone + BIO-300
|
DCAFQN5
|
Naltrexone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Nizatidine + BIO-300
|
DC65TTQ
|
Nizatidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Paromomycin + BIO-300
|
DCO4Z1A
|
Paromomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pazopanib + BIO-300
|
DCNYA6M
|
Pazopanib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
PHA-739358 + BIO-300
|
DCL5XG5
|
PHA-739358
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pramipexole + BIO-300
|
DC2R2FQ
|
Pramipexole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Primidone + BIO-300
|
DC6QCDD
|
Primidone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Procarbazine + BIO-300
|
DCZEGC0
|
Procarbazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Pyrazinamide + BIO-300
|
DCHEFFL
|
Pyrazinamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Quinine + BIO-300
|
DC7MPZV
|
Quinine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Raloxifene + BIO-300
|
DCYE7ND
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Raloxifene + BIO-300
|
DCLW8SE
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Raloxifene + BIO-300
|
DC3CR0N
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Raloxifene + BIO-300
|
DCATXS1
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
Raloxifene + BIO-300
|
DCPCXR9
|
Raloxifene
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
Ramelteon + BIO-300
|
DCG93FO
|
Ramelteon
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Ruxolitinib + BIO-300
|
DCUIRX3
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Ruxolitinib + BIO-300
|
DC2P74V
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Ruxolitinib + BIO-300
|
DCVYSSU
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Ruxolitinib + BIO-300
|
DC4PF2V
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Ruxolitinib + BIO-300
|
DC4MCGT
|
Ruxolitinib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Ruxolitinib + BIO-300
|
DC13ZLD
|
Ruxolitinib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Ruxolitinib + BIO-300
|
DCE6AFQ
|
Ruxolitinib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Ruxolitinib + BIO-300
|
DCS0974
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
Ruxolitinib + BIO-300
|
DCCHRGE
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
Ruxolitinib + BIO-300
|
DC3IRXG
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
Ruxolitinib + BIO-300
|
DC6ORWL
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
Sitagliptin + BIO-300
|
DCPYCLD
|
Sitagliptin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Sivelestat + BIO-300
|
DC18KFP
|
Sivelestat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Sorafenib + BIO-300
|
DCCP6Q0
|
Sorafenib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Sumatriptan + BIO-300
|
DC4RC5D
|
Sumatriptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Testosterone + BIO-300
|
DCFDBDW
|
Testosterone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Tetracycline + BIO-300
|
DCHT0SM
|
Tetracycline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Tindamax + BIO-300
|
DCWY45C
|
Tindamax
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Tolazoline + BIO-300
|
DCP0E8C
|
Tolazoline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Triflupromazine + BIO-300
|
DC84SKD
|
Triflupromazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Trifluridine + BIO-300
|
DCY7ZHX
|
Trifluridine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Trifluridine + BIO-300
|
DCL6AJQ
|
Trifluridine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Trifluridine + BIO-300
|
DC0OHGJ
|
Trifluridine
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Trifluridine + BIO-300
|
DC0ZR6E
|
Trifluridine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Trifluridine + BIO-300
|
DCINT2H
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Trifluridine + BIO-300
|
DCSM3DO
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
Trifluridine + BIO-300
|
DC1O710
|
Trifluridine
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
Trihexyphenidyl + BIO-300
|
DCM6ZLU
|
Trihexyphenidyl
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Trioxsalen + BIO-300
|
DCC6XU7
|
Trioxsalen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Vandetanib + BIO-300
|
DCGNJEC
|
Vandetanib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vandetanib + BIO-300
|
DCNZ1HL
|
Vandetanib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vandetanib + BIO-300
|
DCJAPOL
|
Vandetanib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vandetanib + BIO-300
|
DCJRHJW
|
Vandetanib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
Vandetanib + BIO-300
|
DC5DAFB
|
Vandetanib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
Vandetanib + BIO-300
|
DCQ0TM0
|
Vandetanib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
Vandetanib + BIO-300
|
DCJ8PI0
|
Vandetanib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
Vandetanib + BIO-300
|
DCSHWMM
|
Vandetanib
|
Adenocarcinoma (Cell Line: SW-620)
|
[5] |
|
Vandetanib + BIO-300
|
DCFN6A0
|
Vandetanib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
Vandetanib + BIO-300
|
DC2II6Y
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
Vandetanib + BIO-300
|
DC0LBGX
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
Vandetanib + BIO-300
|
DCLTYCS
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[5] |
|
Vandetanib + BIO-300
|
DCHCF7A
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
Vandetanib + BIO-300
|
DC72BDY
|
Vandetanib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[5] |
|
Vandetanib + BIO-300
|
DCECMRV
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[5] |
|
Vandetanib + BIO-300
|
DCHUYWQ
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[5] |
|
Vandetanib + BIO-300
|
DCMAUR4
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[5] |
|
Vandetanib + BIO-300
|
DCLX3W4
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[5] |
|
Vandetanib + BIO-300
|
DCRVM8S
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[5] |
|
Vandetanib + BIO-300
|
DC20HZ6
|
Vandetanib
|
Glioblastoma (Cell Line: SNB-75)
|
[5] |
|
Vandetanib + BIO-300
|
DCRY9UF
|
Vandetanib
|
Glioma (Cell Line: SF-539)
|
[5] |
|
Vandetanib + BIO-300
|
DCFOLF4
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
Vandetanib + BIO-300
|
DCLNSBZ
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
Vandetanib + BIO-300
|
DCF7P2N
|
Vandetanib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[5] |
|
Vandetanib + BIO-300
|
DCES9SL
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
Vandetanib + BIO-300
|
DCTP3ND
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[5] |
|
Vandetanib + BIO-300
|
DCVEIY9
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
Vandetanib + BIO-300
|
DC4IQGZ
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
Vandetanib + BIO-300
|
DC8N42H
|
Vandetanib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
Vandetanib + BIO-300
|
DCQ0HB8
|
Vandetanib
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
Vandetanib + BIO-300
|
DC4FEHL
|
Vandetanib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
Vandetanib + BIO-300
|
DCSBRCU
|
Vandetanib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
Vandetanib + BIO-300
|
DCWYOQ0
|
Vandetanib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
Vandetanib + BIO-300
|
DCXSFAC
|
Vandetanib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[5] |
|
Vandetanib + BIO-300
|
DC0ZD4B
|
Vandetanib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
Vandetanib + BIO-300
|
DCDA9VU
|
Vandetanib
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
|
Vandetanib + BIO-300
|
DCTKM1J
|
Vandetanib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[5] |
|
Vandetanib + BIO-300
|
DC231O1
|
Vandetanib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[5] |
|
Vemurafenib + BIO-300
|
DCAL3G9
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + BIO-300
|
DCSDRSI
|
Vemurafenib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vemurafenib + BIO-300
|
DC5Y4GA
|
Vemurafenib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vemurafenib + BIO-300
|
DCHRESK
|
Vemurafenib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vemurafenib + BIO-300
|
DCHAMDM
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + BIO-300
|
DCIIZ2R
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
Vemurafenib + BIO-300
|
DCOKI2P
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[5] |
|
Vemurafenib + BIO-300
|
DCFKYUC
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[5] |
|
Vemurafenib + BIO-300
|
DCK10LF
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[5] |
|
Vemurafenib + BIO-300
|
DCWWEU2
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[5] |
|
Vemurafenib + BIO-300
|
DCPYZC1
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[5] |
|
Vemurafenib + BIO-300
|
DC8S4R5
|
Vemurafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[5] |
|
Vemurafenib + BIO-300
|
DCY211K
|
Vemurafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[5] |
|
Vemurafenib + BIO-300
|
DCJL4GD
|
Vemurafenib
|
Glioma (Cell Line: SF-539)
|
[5] |
|
Vemurafenib + BIO-300
|
DCO0U6R
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
Vemurafenib + BIO-300
|
DCE96GM
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[5] |
|
Vemurafenib + BIO-300
|
DCVFHJ2
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[5] |
|
Vemurafenib + BIO-300
|
DC129IN
|
Vemurafenib
|
Melanoma (Cell Line: MALME-3M)
|
[5] |
|
Vemurafenib + BIO-300
|
DCQJLFT
|
Vemurafenib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
Vemurafenib + BIO-300
|
DCXSVR7
|
Vemurafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[5] |
|
Vemurafenib + BIO-300
|
DCT015L
|
Vemurafenib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[5] |
|
Vemurafenib + BIO-300
|
DCR6XPJ
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[5] |
|
Vismodegib + BIO-300
|
DCM7B0F
|
Vismodegib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Vismodegib + BIO-300
|
DCYR7W6
|
Vismodegib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vismodegib + BIO-300
|
DCABYCK
|
Vismodegib
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Vismodegib + BIO-300
|
DC8LSL0
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vismodegib + BIO-300
|
DC0WA3Y
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vismodegib + BIO-300
|
DC6K8PZ
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[5] |
|
Vismodegib + BIO-300
|
DCDRGWC
|
Vismodegib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[5] |
|
Vismodegib + BIO-300
|
DCFQ00K
|
Vismodegib
|
Adenocarcinoma (Cell Line: A549)
|
[5] |
|
Vismodegib + BIO-300
|
DCKP4VP
|
Vismodegib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[5] |
|
Vismodegib + BIO-300
|
DCUZR7D
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCT116)
|
[5] |
|
Vismodegib + BIO-300
|
DCSRZBV
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[5] |
|
Vismodegib + BIO-300
|
DCFAOYW
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[5] |
|
Vismodegib + BIO-300
|
DCZFKNE
|
Vismodegib
|
Adenocarcinoma (Cell Line: HT29)
|
[5] |
|
Vismodegib + BIO-300
|
DCPVFKO
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[5] |
|
Vismodegib + BIO-300
|
DCY8O52
|
Vismodegib
|
Astrocytoma (Cell Line: U251)
|
[5] |
|
Vismodegib + BIO-300
|
DCK1XRD
|
Vismodegib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[5] |
|
Vismodegib + BIO-300
|
DCL2OXC
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[5] |
|
Vismodegib + BIO-300
|
DCJZYZJ
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[5] |
|
Vismodegib + BIO-300
|
DCLFOVV
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[5] |
|
Vismodegib + BIO-300
|
DC0YUE8
|
Vismodegib
|
Glioma (Cell Line: SF-295)
|
[5] |
|
Vismodegib + BIO-300
|
DCAMVES
|
Vismodegib
|
Glioma (Cell Line: SF-539)
|
[5] |
|
Vismodegib + BIO-300
|
DCNJ83Z
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[5] |
|
Vismodegib + BIO-300
|
DCWFIGC
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[5] |
|
Vismodegib + BIO-300
|
DCZ8WGE
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[5] |
|
Vismodegib + BIO-300
|
DCGAL8F
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[5] |
|
Vismodegib + BIO-300
|
DCMAU9X
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[5] |
|
Vismodegib + BIO-300
|
DCE18U0
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[5] |
|
Vismodegib + BIO-300
|
DCG6N3M
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[5] |
|
Vismodegib + BIO-300
|
DCY1OX5
|
Vismodegib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[5] |
|
Vismodegib + BIO-300
|
DCETPJ9
|
Vismodegib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[5] |
|
Vismodegib + BIO-300
|
DC4TFTA
|
Vismodegib
|
Prostate carcinoma (Cell Line: PC-3)
|
[5] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
